Advertisement

Early Postoperative Intraperitoneal Chemotherapy: Current Role and Future Perspectives

  • T. Douchy
  • L. Lemoine
  • K. Van der Speeten
Chapter

Abstract

The introduction of cytoreductive surgery and hyperthermic intraperitoneal perioperative chemotherapy has greatly improved the prognosis of patients with peritoneal carcinomatosis. In spite of these improvements, the majority of patients still die of intra-abdominal dissemination. Several strategies to consolidate and improve these results are being explored. The aim of this manuscript is to evaluate early postoperative intraperitoneal chemotherapy as a possible leverage point to further improve multimodal therapy of peritoneal carcinomatosis.

Keywords

EPIC Clinical evidence for EPIC EPIC drug regimens HIPEC 5-FU Taxanes Peritoneal carcinomatosis 

Abbreviations

AUC

Area under the curve

BIC

Bidirectional intraoperative chemotherapy

CCR

Completeness of cytoreduction

CRC

Colorectal carcinoma

CRS

Cytoreductive surgery

DMPM

Diffuse malignant peritoneal mesothelioma

EPIC

Early postoperative intraperitoneal chemotherapy

FU

Fluorouracil

HIPEC

Hyperthermic intraperitoneal perioperative chemotherapy

IPC

Intraperitoneal chemotherapy

LV

Leucovorin

MMC

Mitomycin C

NA

Not available

NIPS

Neoadjuvant intraperitoneal and systemic chemotherapy

OS

Overall survival

PCI

Peritoneal carcinomatosis index

PFS

Progression-free survival

PM

Peritoneal metastases

SIPC

Sequenced intraperitoneal chemotherapy

Notes

Acknowledgements

Lemoine L. is supported by the Agency for Innovation by Science and Technology (IWT) in Brussels, Belgium. Lemoine L. is a researcher for the Limburg Clinical Research Program (LCRP) UHasselt-ZOL-Jessa, supported by the foundation Limburg Sterk Merk (LSM), Hasselt University, Ziekenhuis Oost-Limburg and Jessa Hospital, Belgium.

Funding 

No conflicts of interest.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Sampson JA. Implantation peritoneal carcinomatosis of ovarian origin. Am J Pathol. 1931;7:423–44.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Barrasa A, Van De Speeten K, Stuart OA, Sugarbaker PH, Zappa L. Rationale for perioperative chemotherapy treatment in peritoneal carcinomatosis. Cir Esp. 2009;85:3–13.PubMedCrossRefGoogle Scholar
  4. 4.
    Brodsky JT, Cohen AM. Peritoneal seeding following potentially curative resection of colonic carcinoma: implications for adjuvant therapy. Dis Colon Rectum. 1991;34:723–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Iitsuka Y, Kaneshima S, Tanida O, Takeuchi T, Koga S. Intraperitoneal free cancer cells and their viability in gastric cancer. Cancer. 1979;44:1476–80.PubMedCrossRefGoogle Scholar
  6. 6.
    Zoetmulder FA. Cancer cell seeding during abdominal surgery: experimental studies. Cancer Treat Res. 1996;82:155–61.PubMedCrossRefGoogle Scholar
  7. 7.
    Sugarbaker PH. The natural history of large bowel cancer: surgical implications. J Exp Clin Cancer Res. 1989;8:41.Google Scholar
  8. 8.
    Hansen E, Wolff N, Knuechel R, Ruschoff J, Hofstaedter F, Taeger K. Tumor cells in blood shed from the surgical field. Arch Surg. 1995;130:387–93.PubMedCrossRefGoogle Scholar
  9. 9.
    Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol. 2003;21:233–48.PubMedCrossRefGoogle Scholar
  10. 10.
    Chu DZJ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63:364–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Spratt JS, Edwards M, Kubota T, Lindberg R, Tseng MT. Peritoneal carcinomatosis: anatomy, physiology, diagnosis, management. Curr Probl Cancer. 1986;10:553–84.CrossRefGoogle Scholar
  12. 12.
    Ketcham S, Pilch H, Morton L. Delayed intestinal obstruction following treatment for cancer. Cancer. 1968;25:406–10.CrossRefGoogle Scholar
  13. 13.
    Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.PubMedCrossRefGoogle Scholar
  14. 14.
    Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–32.PubMedCrossRefGoogle Scholar
  15. 15.
    Isacoff WH, Borud K. Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview. World J Surg. 1997;21:748–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer. 1997;80:1179–87.PubMedCrossRefGoogle Scholar
  17. 17.
    Midgley R, Kerr D. Colorectal cancer. Lancet. 1999;353:391–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Klaver YLB, Lemmens VEPP, Creemers GJ, Rutten HJT, Nienhuijs SW, de Hingh IHJT. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol. 2011;22:2250–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116:3756–62.PubMedCrossRefGoogle Scholar
  20. 20.
    Quere P, Facy O, Manfredi S, Jooste V, Faivre J, Lepage C, et al. Epidemiology, management, and survival of peritoneal carcinomatosis from colorectal cancer: a population-based study. Dis Colon Rectum. 2015;58:743–52.PubMedCrossRefGoogle Scholar
  21. 21.
    Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Douillard J, Cunningham D, Roth A, Navarro M, James R, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–7.PubMedCrossRefGoogle Scholar
  23. 23.
    De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.PubMedCrossRefGoogle Scholar
  24. 24.
    Klaver YLB, Simkens LHJ, Lemmens VEPP, Koopman M, Teerenstra S, Bleichrodt RP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38:617–23.PubMedCrossRefGoogle Scholar
  25. 25.
    Janda M, Youlden DR, Baade PD, Jackson D, Obermair A. Elderly patients with stage III or IV ovarian cancer: should they receive standard care? Int J Gynecol Cancer. 2008;18:896–907.PubMedCrossRefGoogle Scholar
  26. 26.
    Mcguire WP, Hoskins WJ, Brady MF, Kugera PR, Partridge EE, Look KY, et al. Patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer InterGroup. J Clin Oncol. 2009;27:1419–25.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Schmid BC, Oehler MK. New perspectives in ovarian cancer treatment. Maturitas. 2014;77:128–36.PubMedCrossRefGoogle Scholar
  29. 29.
    Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–50.PubMedCrossRefGoogle Scholar
  30. 30.
    Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.PubMedCrossRefGoogle Scholar
  31. 31.
    Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1994;14:254–61.CrossRefGoogle Scholar
  32. 32.
    Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbeck’s Arch Surg. 1999;384:576–87.CrossRefGoogle Scholar
  33. 33.
    Sugarbaker PH. Carcinomatosis – is cure an option? J Clin Oncol. 2003;21:762–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol. 2003;21:799–806.PubMedCrossRefGoogle Scholar
  35. 35.
    Sugarbaker PH. Peritonectomy procedures. Perit Carcinomatosis A Multidiscip Approach. 2007;221:247–64.CrossRefGoogle Scholar
  36. 36.
    Spratt JS, Adcock RA, Sherrill W, Muskovin M, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256–60.PubMedGoogle Scholar
  37. 37.
    Fujimura T, Yonemura Y, Fujita H, Michiwa Y, Kawamura T, Nojima N, et al. Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies. Int Surg. 1999;84:60–6.PubMedGoogle Scholar
  38. 38.
    Beaujard AC, Glehen O, Caillot JL, Francois Y, Bienvenu J, Panteix G, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer. 2000;88:2512–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Cavaliere F, Perri P, Di Filippo F, Giannarelli D, Botti C, Cosimelli M, et al. Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol. 2000;74:41–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Elias D, Blot F, Elotmany A, Antoun S, Lasser P, Boige V, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92:71–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Loggie BW, Fleming RA, Mcquellon RP, Russell GB, Geisinger KR. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg. 2000;66:561–8.PubMedGoogle Scholar
  42. 42.
    Piso P, Bektas H, Werner U, Schlitt HJ, Kubicka S, Bornscheuer A, et al. Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol. 2001;27:286–90.PubMedCrossRefGoogle Scholar
  43. 43.
    Rey Y, Porcheron J, Talabard J, Szafnicki K, Balique J. Peritoneal carcinomatosis treated by cytoreduction surgery and intraperitoneal hyperthermic perfusion. Ann Chir. 2000;125:631–42.PubMedCrossRefGoogle Scholar
  44. 44.
    Schneebaum S, Arnold MW, Staubus A, Young DC, Dumond D, Martin EW. Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Ann Surg Oncol. 1996;3:44–50.PubMedCrossRefGoogle Scholar
  45. 45.
    Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138:26–33.PubMedCrossRefGoogle Scholar
  46. 46.
    Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–31.PubMedCrossRefGoogle Scholar
  47. 47.
    Witkamp AJ, De Bree E, Kaag MM, Boot H, Beijnen JH, Van Slooten GW, et al. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer. 2001;37:979–84.PubMedCrossRefGoogle Scholar
  48. 48.
    Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.PubMedCrossRefGoogle Scholar
  49. 49.
    Verwaal VJ, Van Ruth S, Witkamp A, Boot H, Van Slooten G, Zoetmulder FAN. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65–71.PubMedCrossRefGoogle Scholar
  50. 50.
    Cao C, Yan TD, Black D, Morris DL. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2009;16:2152–65.PubMedCrossRefGoogle Scholar
  51. 51.
    Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients. Cancer. 2010;116:5608–18.PubMedCrossRefGoogle Scholar
  52. 52.
    Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.PubMedCrossRefGoogle Scholar
  53. 53.
    Elias D, Raynard B, Farkhondeh F, Goéré D, Rouquie D, Ciuchendea R, et al. Peritoneal carcinomatosis of colorectal origin. Gastroentérol Clin Biol. 2006;30:1200–4.PubMedCrossRefGoogle Scholar
  54. 54.
    Sugarbaker PH, Schellinx ME, Chang D, Koslowe P, von Meyerfeldt M. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg. 1996;20:585–91.PubMedCrossRefGoogle Scholar
  55. 55.
    Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.PubMedCrossRefGoogle Scholar
  56. 56.
    Macrì A, Saladino E, Bartolo V, Adamo V, Altavilla G, Mondello E, et al. Peritoneal carcinomatosis of colorectal origin. Gastroentérol Clin Biol. 2006;30:1200–4.CrossRefGoogle Scholar
  57. 57.
    Sweitzer KL, Nathanson SD, Nelson LT, Zachary C. Irrigation does not dislodge or destroy tumor cells adherent to the tumor bed. J Surg Oncol. 1993;53:184–90.PubMedCrossRefGoogle Scholar
  58. 58.
    Jacquet P, Elias D, Sugarbaker PH. Tumor implantation in cicatrization sites following surgery for digestive cancers. J Chir (Paris). 1996;133:175–82.Google Scholar
  59. 59.
    Willett C, Tepper JE, Cohen A, Orlow E, Welch C. Obstructive and perforative colonic carcinoma: patterns of failure al hospital (MGH) experience in these patients. J Clin Oncol. 1985;3:379–84.PubMedCrossRefGoogle Scholar
  60. 60.
    Slanetz CA. The effect of inadvertent intraoperative perforation on survival and recurrence in colorectal cancer. Dis Colon Rectum. 1984;27:792–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Elias D, Goéré D, Di Pietrantonio D, Boige V, Malka D, Kohneh-Shahri N, et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2008;247:445–50.PubMedCrossRefGoogle Scholar
  62. 62.
    Shepherd NA, Baxter KJ, Love SB. The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology. 1997;112:1096–102.PubMedCrossRefGoogle Scholar
  63. 63.
    Sammartino P, Sibio S, Biacchi D, Cardi M, Mingazzini P, Rosati MS, et al. Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. Int J Color Dis. 2014;29(9):1081.CrossRefGoogle Scholar
  64. 64.
    Ceelen W, Van Nieuwenhove Y, Putte DV, Pattyn P. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ann Surg Oncol. 2014;21:3023–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Waite K, Youssef H. The role of neoadjuvant and adjuvant systemic chemotherapy with cytoreductive surgery and heated intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review. Ann Surg Oncol. 2017;24:705–20.PubMedCrossRefGoogle Scholar
  66. 66.
    Chua TC, Morris DL, Saxena A, Esquivel J, Liauw W, Doerfer J, et al. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol. 2011;18:1560–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Van Der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. Pharmacology of perioperative 5-fluorouracil. J Surg Oncol. 2010;102:730–5.PubMedCrossRefGoogle Scholar
  68. 68.
    Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El Otmany A, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–72.PubMedCrossRefGoogle Scholar
  69. 69.
    Van Der Speeten K, Govaerts K, Stuart OA, Sugarbaker PH. Pharmacokinetics of the perioperative use of cancer chemotherapy in peritoneal surface malignancy patients. Gastroenterol Res Pract. 2012;2012:378064.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Van der Speeten K, Anthony Stuart O, Sugarbaker PH. Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy. Surg Oncol Clin N Am. 2012;21:577–97.PubMedCrossRefGoogle Scholar
  71. 71.
    Van der Speeten K. A Pharmacokinetic and pharmacodynamic rationale for perioperative cancer chemotherapy in patient with peritoneal carcinomatosis. 2010.Google Scholar
  72. 72.
    Yonemura Y, Bandou E, Sawa T, Yoshimitsu Y, Endou Y, Sasaki T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32:661–5.PubMedCrossRefGoogle Scholar
  73. 73.
    Sugarbaker PH. Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy. Cancer Treat Res. 1996;82:317–25.PubMedCrossRefGoogle Scholar
  74. 74.
    Zylberberg B, Dormont D, Janklewicz S, Darai E, Bretel JJ, Poncelet C, et al. Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer. Eur J Gynaecol Oncol. 2001;22:40–5.PubMedGoogle Scholar
  75. 75.
    Yonemura Y, Ishibashi H, Hirano M, Mizumoto A, Takeshita K, Noguchi K, et al. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol. 2016;24(2):478–85.PubMedCrossRefGoogle Scholar
  76. 76.
    Yonemura Y, Elnemr A, Endou Y, Ishibashi H, Mizumoto A, Miura M, et al. Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol. 2012;2012:8.Google Scholar
  77. 77.
    Esquivel J, Vidal-Jove J, Steves M, Sugarbaker P. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery. 1993;113:631–6.PubMedGoogle Scholar
  78. 78.
    Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol. 2007;18:1943–50.PubMedCrossRefGoogle Scholar
  79. 79.
    Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681.PubMedCrossRefGoogle Scholar
  80. 80.
    Jaaback K, Johnson N, TA L, Lawrie Theresa A. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;11:CD005340.Google Scholar
  81. 81.
    Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecol. J Clin Oncol. 2001;19:1001–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.PubMedCrossRefGoogle Scholar
  83. 83.
    Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol. 1994;12:970–4.PubMedCrossRefGoogle Scholar
  84. 84.
    Cheong J-H, Shen JY, Song CS, Hyung WJ, Shen JG, Choi SH, et al. Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer. Ann Surg Oncol. 2006;14:61–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1–11.PubMedGoogle Scholar
  86. 86.
    Dedrick RL. Theoretical and experimental bases of intra- peritoneal chemotherapy. Semin Oncol. 1985;12:1–6.PubMedGoogle Scholar
  87. 87.
    Sugarbaker PH, Graves T, DeBruijn E, Cunliffe W, Mullins R, Hull W, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res. 1990;50:5790–4.PubMedGoogle Scholar
  88. 88.
    Flessner MF, Lofthouse J, Zakaria ER. Improving contact area between the peritoneum and intraperitoneal therapeutic solutions. J Am Soc Nephrol. 2001;12:807–13.PubMedGoogle Scholar
  89. 89.
    Chagnac A, Herskovitz P, Weinstein T, Elyashiv S, Hirsh J, Hammel I, et al. The peritoneal membrane in peritoneal dialysis patients: estimation of its functional surface area by applying stereologic methods to computerized tomography scans. J Am Soc Nephrol. 1999;10:342–6.PubMedGoogle Scholar
  90. 90.
    Chagnac A, Herskovitz P, Ori Y, Weinstein T, Hirsh J, Katz M, et al. Effect of increased dialysate volume on peritoneal surface area among peritoneal dialysis patients. J Am Soc Nephrol. 2002;13:2554–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Flessner MF, Lofthouse J, Williams A. Increasing peritoneal contact area during dialysis improves mass transfer. J Am Soc Nephrol. 2001;12:2139–45.PubMedGoogle Scholar
  92. 92.
    Rosenshein N, Blake D, McIntyre PA, Parmley T, Natarajan TK, Dvornicky J, et al. The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecol Oncol. 1978;6:106–10.PubMedCrossRefGoogle Scholar
  93. 93.
    Graf W, Westlin JE, Pahlman L, Glimelius B. Adjuvant intraperitoneal 5-fluorouracil and intravenous leucovorin after colorectal cancer surgery: a randomized phase II placebo- controlled study. Int J Color Dis. 1994;9:35–9.CrossRefGoogle Scholar
  94. 94.
    Elias D, Antoun S, Raynard B, Puizillout JM, Sabourin JC, Ducreux M, et al. Treatment of peritoneal carcinomatosis using complete excision and intraperitoneal chemohyperthermia. A phase I-II study defining the best technical procedures. Chirurgie. 1999;124:380–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Los G, Mutsaers PH, Lenglet WJ, Baldew GS, McVie JG. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol. 1990;25:389–94.PubMedCrossRefGoogle Scholar
  96. 96.
    Los G, Verdegaal EME, Mutsaers PHA, McVie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159–65.PubMedCrossRefGoogle Scholar
  97. 97.
    Ozols RF, Grotzinger KR, Young RC, Locker GY, Doroshow JH, Myers CE. Pharmacokinetics of Adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 1979;39:3209–14.PubMedGoogle Scholar
  98. 98.
    Ceelen WP, Flessner MF. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol. 2010;7:108–15.PubMedCrossRefGoogle Scholar
  99. 99.
    Hasovits C, Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin Pharmacokinet. 2012;51:203–24.PubMedCrossRefGoogle Scholar
  100. 100.
    Fuertes MA, Alonso C, Pérez JM. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev. 2003;103:645–62.PubMedCrossRefGoogle Scholar
  101. 101.
    Link KH, Leder G, Pillasch J, Butzer U, Staib L, Kornmann M, et al. In vitro concentration response studies and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols. Semin Surg Oncol. 1998;14:189–201.PubMedCrossRefGoogle Scholar
  102. 102.
    Sugarbaker P, Cunliffe W, Belliveau A. Rationale for early postoperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy. Regul Cancer Treat. 1989;10:66–79.Google Scholar
  103. 103.
    Weiss L. Metastatic inefficiency: causes and consequences. Cancer Rev. 1986;54:1–24.Google Scholar
  104. 104.
    Panis Y, Ribeiro J, Chrétien Y, Nordlinger B. Dormant liver metastases: an experimental study. Br J Surg. 1992;79(3):221.PubMedCrossRefGoogle Scholar
  105. 105.
    Eggermont AM, Steller EP, Sugarbaker PH. Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery. 1987;102:71–8.PubMedGoogle Scholar
  106. 106.
    Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey FJ, Eilber FR. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol. 1999;6:645–50.PubMedCrossRefGoogle Scholar
  107. 107.
    Vaillant JC, Nordlinger B, Deuffic S, Arnaud JP, Pelissier E, Favre JP, et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: a multicenter phase III trial. Ann Surg. 2000;231:449–56.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Jacquet P, Averbach A, Stephens AD, Anthony Stuart O, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55:130–8.PubMedCrossRefGoogle Scholar
  109. 109.
    White SK, Stephens AD, Sugarbaker PH. Hyperthermic intraoperative intraperitoneal chemotherapy safety considerations. AORN J. 1996;63:716–24.PubMedCrossRefGoogle Scholar
  110. 110.
    Al-Quteimat OM, Al-Badaineh MA. Intraperitoneal chemotherapy: rationale, applications, and limitations. J Oncol Pharm Pract. 2014;20:369–80.PubMedCrossRefGoogle Scholar
  111. 111.
    Chua TC, Liauw W, Zhao J, Morris DL. Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis. Int J Clin Oncol. 2013;18:439–46.PubMedCrossRefGoogle Scholar
  112. 112.
    Mahteme H, Hansson J, Berglund Å, Påhlman L, Glimelius B, Nygren P, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer. 2004;90:403–7.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221:124–32.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Pestieau S, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Dis Colon Rectum. 2000;43:1341–8.PubMedCrossRefGoogle Scholar
  115. 115.
    Carmignani CP, Ortega-Perez G, Sugarbaker PH. The management of synchronous peritoneal carcinomatosis and hematogenous metastasis from colorectal cancer. Eur J Surg Oncol. 2004;30:391–8.PubMedCrossRefGoogle Scholar
  116. 116.
    Elias D, Delperro J-R, Sideris L, Benhamou E, Pocard M, Baton O, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004;11:518–21.PubMedCrossRefGoogle Scholar
  117. 117.
    Gómez Portilla A, Barrios P, Rufian S, Camps B, Bretcha P, Gonzalez Bayon L, et al. Management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Eur J Surg Oncol. 2006;32:628–31.PubMedCrossRefGoogle Scholar
  118. 118.
    da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203:878–86.PubMedCrossRefGoogle Scholar
  119. 119.
    Elias D, Benizri E, Dipietrantonio D, Menegon P, Malka D, Raynard B. Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2006;14:509–14.PubMedCrossRefGoogle Scholar
  120. 120.
    Hadi R, Saunders V, Utkina O, Clingan P, Kam P, Links M, et al. Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J Surg. 2006;76:156–61.PubMedCrossRefGoogle Scholar
  121. 121.
    Yan TD, Chu F, Links M, Kam PC, Glenn D, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival. Eur J Surg Oncol. 2006;32:1119–24.PubMedCrossRefGoogle Scholar
  122. 122.
    Füzün M, Sökmen S, Terzi C, Canda AE. Cytoreductive approach to peritoneal carcinomatosis originated from colorectal cancer: Turkish experience. Acta Chir Iugosl. 2006;53:17–21.PubMedCrossRefGoogle Scholar
  123. 123.
    Hansson J, Graf W, Påhlman L, Nygren P, Mahteme H. Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2008;35:202–8.PubMedCrossRefGoogle Scholar
  124. 124.
    Saxena A, Yan TD, Morris DL. A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg. 2010;34:70–8.PubMedCrossRefGoogle Scholar
  125. 125.
    Elias D, Glehen O, Pocard M, Quenet F, Goéré D, Arvieux C, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010;251:896–901.PubMedCrossRefGoogle Scholar
  126. 126.
    Lam JY, McConnell YJ, Rivard JD, Temple WJ, Mack LA. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. Am J Surg. 2015;210:424–30.PubMedCrossRefGoogle Scholar
  127. 127.
    Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg. 1998;228:347–54.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Kwon OK, Chung HY, WS Y. Early postoperative intraperitoneal chemotherapy for gastric cancer. Cancer Treat Res. 2014;55:265–75.Google Scholar
  129. 129.
    Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43(7):1228–35.PubMedCrossRefGoogle Scholar
  130. 130.
    Yan TD, Marquardt CE, Sugarbaker PH. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma—a prospective study of 70 consecutive cases. Ann Surg Oncol. 2006;14:515–25.PubMedCrossRefGoogle Scholar
  131. 131.
    Sugarbaker PH, Gianola FJ, Speyer JC, Wesley R, Barofsky I, Meyers CE, et al. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery. 1985;98:414–22.PubMedGoogle Scholar
  132. 132.
    Park J-G, Kramer BS, Steinberg SM, Carmichael J, Collins M, Minna JD, et al. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetrie assay. Cancer Res. 1987;47:5875–9.PubMedGoogle Scholar
  133. 133.
    Jol C, Kuppem P, Leeflang P, van Oosterom A, Tjaden U, De Bruijn E. In vitro human ovarian cancer. In: Taguchi T, Andryse O, editors. New trends in cancer chemotherapy with mitomycin C, vol. 18. Amsterdam: Excerpta Medica; 1987. p. 181–91.Google Scholar
  134. 134.
    Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MH, Eng C, et al. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol. 2009;16:2181–7.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Lyman G, Lyman C, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10:427–37.PubMedCrossRefGoogle Scholar
  136. 136.
    Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer H, et al. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 1980;40:567–72.PubMedGoogle Scholar
  137. 137.
    Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg. 2001;25:985–90.PubMedCrossRefGoogle Scholar
  138. 138.
    Pestieau SR, Schnake KJ, Stuart OA, Sugarbaker PH. Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 2001;47:269–76.PubMedCrossRefGoogle Scholar
  139. 139.
    Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605–21.PubMedCrossRefGoogle Scholar
  140. 140.
    Mohamed F, Marchettini P, Stuart OA, Yoo D, Sugarbaker PH. A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. Eur J Surg Oncol. 2003;29:261–5.PubMedCrossRefGoogle Scholar
  141. 141.
    Jacquet P, Stuart OA, Dalton R, Chang D, Sugarbaker PH. Effect of intraperitoneal chemotherapy and fibrinolytic therapy on tumor implantation in wound sites. J. Surg. Oncol. 1996;62:128–34.PubMedCrossRefGoogle Scholar
  142. 142.
    Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol. 2006;57:703–8.PubMedCrossRefGoogle Scholar
  143. 143.
    Muggia FM, Peters GJ, Landolph JRJ. XIII International Charles Heidelberger Symposium and 50 years of fluoropyrimidines in cancer therapy held on September 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center. Mol Cancer Ther. 2009;8:992–9.PubMedCrossRefGoogle Scholar
  144. 144.
    Papamichael D. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status. Oncologist. 1999;18:478–87.Google Scholar
  145. 145.
    Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry. 1974;13:471–81.PubMedCrossRefGoogle Scholar
  146. 146.
    Diasio RB, Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol. 1994;12:2239–42.PubMedCrossRefGoogle Scholar
  147. 147.
    Theodoropoulos PA, Polioudaki H, Kostaki O, Dargemont C, Georgatos SD. Taxol affects nuclear lamina and pore complex organization and inhibits import of Karyophilic proteins into the cell nucleus Taxol affects nuclear lamina and pore complex organization and inhibits import of Karyophilic proteins into the cell. Nucleus. 1999;59:4625–33.Google Scholar
  148. 148.
    Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer. 1999;83:151–6.PubMedCrossRefGoogle Scholar
  149. 149.
    Herbst RS, Khuri FR. Mode of action of docetaxel – a basis for combination with novel anticancer agents. Cancer Treat Rev. 2003;29:407–15.PubMedCrossRefGoogle Scholar
  150. 150.
    de Bree E, Rosing H, Michalakis J, Romanos J, Relakis K, Theodoropoulos PA, et al. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32:666–70.PubMedCrossRefGoogle Scholar
  151. 151.
    Mohamed F, Sugarbaker PH. Intraperitoneal taxanes. Surg Oncol Clin N Am. 2003;12:825–33.PubMedCrossRefGoogle Scholar
  152. 152.
    Yu W, Whang I, Averbach A, Chang D, Sugarbaker PH. Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer. Am Surg. 1998;64:1104–8.PubMedGoogle Scholar
  153. 153.
    Elias D, Sideris L, Pocard M, Edè C, Hassouna DB, Ducreux M, et al. Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients. Ann Oncol. 2004;15:781–5.PubMedCrossRefGoogle Scholar
  154. 154.
    Dindo D, Demartines N, Clavien P-A. Classification of surgical complications. Ann Surg. 2004;240:205–13.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Scheithauer W, Kornek G, Roseq H, Sebesta C, Marcell A, Kwasny W, et al. Combined Intraperitoneal plus intravenous chemotherapy curative resection for colonic adenocarcinoma after. Eur J Cancer. 1981;3:1981–6.Google Scholar
  156. 156.
    Schilsky RL, Choi KE, Grayhack J, Grimmer D, Guarnieri C, Fullem L. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol. 1990;8(12):2054–6.PubMedCrossRefGoogle Scholar
  157. 157.
    Karadayi K, Yildiz C, Karakus S, Bozoklu Akkar O, Pakay Ugurlu G, Kurt A, et al. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for gynecological malignancies: a single center experience. Eur J Gynaecol Oncol. 2016;37:194–8.PubMedGoogle Scholar
  158. 158.
    Xanthoulis A, Mirelis C, Markakidis S, Bougioukas I, Bekiaridou K, Tsalkidou E, et al. Complete cytoreduction combined with early postoperative intraperitoneal chemotherapy for ovarian carcinosarcoma: report of two cases. Gynecol Obstet Investig. 2006;62:100–2.CrossRefGoogle Scholar
  159. 159.
    Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–5.PubMedCrossRefGoogle Scholar
  160. 160.
    Chan DL, Morris DL, Rao A, Chua TC. Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Manag Res. 2012;4:413–22.PubMedPubMedCentralGoogle Scholar
  161. 161.
    Cenitagoya GF, Bergh CK, Klinger-Roitman J. A prospective study of gastric cancer: “real” 5-year survival rates. Dig Surg. 1998;15:317–22.PubMedCrossRefGoogle Scholar
  162. 162.
    Akoh JA, Macintyre IM. Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br J Surg. 1992;79:293–9.PubMedCrossRefGoogle Scholar
  163. 163.
    Choi AH, Kim J, Chao J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World J Gastroenterol. 2015;21:7343–8.PubMedPubMedCentralCrossRefGoogle Scholar
  164. 164.
    Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268–73.PubMedCrossRefGoogle Scholar
  165. 165.
    Macdonald JS, Smalley SR, Jacqueline B, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.PubMedCrossRefGoogle Scholar
  166. 166.
    Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.PubMedCrossRefGoogle Scholar
  167. 167.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.PubMedCrossRefGoogle Scholar
  168. 168.
    Hallissey MT, Dunn JA, Ward LC, Allum W. The second British stomach cancer group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet. 1994;343:1309–12.PubMedCrossRefGoogle Scholar
  169. 169.
    Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.PubMedCrossRefGoogle Scholar
  170. 170.
    Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982;8:1–11.PubMedCrossRefGoogle Scholar
  171. 171.
    Wisbeck WM, Becher EM, Russell AH. Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologist. Radiother Oncol. 1986;7:13–8.PubMedCrossRefGoogle Scholar
  172. 172.
    Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32:686–91.PubMedCrossRefGoogle Scholar
  173. 173.
    Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol. 2012;13:362–9.CrossRefGoogle Scholar
  174. 174.
    Evrard S, Mazière C, Désolneux G. HIPEC: standard of care or an experimental approach? Lancet Oncol. 2012;13:462–3.CrossRefGoogle Scholar
  175. 175.
    Désolneux G, Mazière C, Vara J, Brouste V, Fonck M, Béchade D, et al. Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only. PLoS One. 2015;10:1–12.CrossRefGoogle Scholar
  176. 176.
    Klaver YLB, Hendriks T, Lomme RMLM, Rutten HJT, Bleichrodt RP, de Hingh IHJT, et al. Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study. Ann Surg Oncol. 2012;19(Suppl 3):S475–82.PubMedCrossRefGoogle Scholar
  177. 177.
    Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg. 2010;251:640–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of Surgical OncologyZiekenhuis Oost-LimburgGenkBelgium
  2. 2.Department of Biochemistry, Faculty of MedicineUniversity HasseltDiepenbeekBelgium
  3. 3.Washington Cancer Institute, Washington Hospital CenterWashington, DCUSA

Personalised recommendations